血清标志物对社区获得性肺炎的诊断及预后的影响

doi:10.3969/j.issn.1002-1949.2019.01.017

摘要
图/表
参考文献(56)
相关文章 (15)

全文: PDF (478 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要社区获得性肺炎目前仍是发达国家和发展中国家的主要死亡原因，早期发现社区获得性肺炎(community-acquired pneumonia, CAP)患者预后不良风险是减少病死率的关键，其可能对医疗资源的消耗及后续治疗产生影响。目前多采用评分系统预测CAP患者的预后，但存在一定局限性，当前多项研究表明，多种血清标志物在CAP诊断、预后评估及治疗中均具有重要意义。本文旨在总结近年来针对CAP患者的诊断和预后有影响价值的相关血清标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张楠
	朱华栋

关键词 ：社区获得性肺炎（CAP）, 降钙素原, C-反应蛋白, D-二聚体(D-Dimer), 中性粒细胞百分比（NCP）, 中性粒细胞/淋巴细胞比值（NLR）, 白细胞介素-6（IL-6）

基金资助:中国医学科学院医学与健康科技创新工程（2017-l2M-1-009）

通讯作者: 朱华栋（1970-），男，主任医师，教授，博士生导师，E-mail： zhuhuadong1970@126.com。

作者简介: 张楠（1992-），女，硕士研究生，住院医师，E-mail: 907533944@qq.com。

引用本文:

张楠，朱华栋. 血清标志物对社区获得性肺炎的诊断及预后的影响[J]. 中国急救医学, 2019, 39(1): 82-87.
Zhang Nan, Zhu Hua-dong. Effect of serum markerson the diagnosis and prognosis of community acquired pneumonia. Chinese Journal of Critical Care Medicine, 2019, 39(1): 82-87.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2019.01.017 或 http://www.cnemergency.org.cn/CN/Y2019/V39/I1/82

［1］中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)［J］. 中华结核和呼吸杂志， 2016, 39(4):253-279. ［2］Shaddock EJ. How and when to use common biomarkers in community-acquired pneumonia［J］. Pneumonia (Nathan), 2016, 8:17. ［3］Seligman R, Ramos-Lima LF, Oliveira Vdo A, et al. Biomarkers in community-acquired pneumonia: a state-of-the-art review［J］. Clinics (Sao Paulo), 2012, 67(11):1321-1325. ［4］Viasus D, Simonetti A, Garcia-Vidal C, et al. Prediction of prognosis by markers in community-acquired pneumonia［J］. Expert Rev Anti Infect Ther, 2013, 11(9):917-929. ［5］Khan F, Owens MB, Restrepo M, et al. Tools for outcome prediction in patients with community acquired pneumonia［J］. Expert Rev Clin Pharmacol, 2017, 10(2):201-211.  ［6］Gilbert DN. Role of Procalcitonin in the Management of Infected Patients in the Intensive Care Unit［J］. Infect Dis Clin North Am, 2017, 31(3):435-453.  ［7］Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia［J］. Clin Infect Dis, 2017, 65(2):183-190.  ［8］Rodriguez AH, Avilés-Jurado FX2, Díaz E, et al. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis［J］. J infect, 2016, 72(2):143-151. ［9］Masiá M, Padilla S, Ortiz de la Tabla V, et al. Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial［J］. PLoS One, 2017, 12(4):e0175634.〖ZK)〗 ［10］Ito A, Ishida T, Tokumasu H, et al. Impact of procalcitonin-guided therapy for hospitalized community-acquired pneumonia on reducing antibiotic consumption and costs in Japan［J］. J Infect Chemother, 2017, 23(3):142-147. ［11］Walsh TL, DiSilvio BE, Hammer C, et al. Impact of Procalcitonin Guidance with an Educational Program on Management of Adults Hospitalized with Pneumonia［J］. Am J Med, 2018, 131(2):201.e1-201.e8. ［12］Lindstrom ST, Wong EK. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia［J］. Intern Med J, 2014, 44(4):390-397. ［13］Kim MW, Lim JY, Oh SH. Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia［J］. Scand J Clin Lab Invest, 2017, 77(7):486-492. ［14］Fernandes L, Arora AS, Mesquita AM. Role of Semi-quantitative Serum Procalcitonin in Assessing Prognosis of Community Acquired Bacterial Pneumonia Compared to PORT PSI, CURB-65 and CRB-65［J］. J Clin Diagn Res, 2015, 9(7):OC01-4. ［15］Kim JH, Seo JW, Mok JH, et al. Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia［J］. Tuberc Respiratory Dis(Seoul), 2013, 74(5):207-214. ［16］McCluskey SM, Schuetz P, Abers MS, et al. Serial Procalcitonin as a Predictor of Bacteremia and Need for Intensive Care Unit Care in Adults With Pneumonia, Including Those With Highest Severity: A Prospective Cohort Study［J］. Open Forum Infect Dis, 2017, 4(1):ofw238. ［17］Pilotto A, Dini S, Daragjati J, et al. Combined use of the multidimensional prognostic index (MPI) and procalcitonin serum levels in predicting 1-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP): a prospective study［J］. Aging Clin Exp Res, 2018, 30(2):193-197. ［18］Zhydkov A, Christ-Crain M, Thomann R, et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in communityacquired pneumonia［J］. Clin Chem Lab Med, 2015, 53(4):559-566. ［19］Self WH, Grijalva CG, Williams DJ, et al. Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia［J］. Chest, 2016, 150(4):819-828. ［20］Naderi HR, Sheybani F, Sarvghad M, et al. Can Procalcitonin Add to the Prognostic Power of the Severity Scoring System in Adults with Pneumonia［J］.Tanaffos, 2015, 14(2):95-106. ［21］Prucha M, Bellingan G, Zazula R. Sepsis biomarkers［J］. Clinica chimica acta, 2015, 440:97-103. ［22］Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia［J］. Am J Med, 2008, 121(3):219-225. ［23］Tamayose M, Fujita J, Parrott G, et al. Correlations between extent of X-ray infiltration and levels of serum C-reactive protein in adult non-severe community-acquired pneumonia［J］. J Infect Chemother, 2015, 21(6):456-463. ［24］Hohenthal U, Hurme S, Helenius H, et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia［J］. Clin Microbiol Infect, 2009, 15(11):1026-1032. ［25］Nseir W, Farah R, Mograbi J, et al. Impact of serum C-reactive protein measurements in the first 2 days on the 30-day mortality in hospitalized patients with severe community-acquired pneumonia: a cohort study［J］. J Crit care, 2013, 28(3):291-295. ［26］Andersen SB, Baunbaek Egelund G, Jensen AV, et al. Failure of CRP decline within three days of hospitalization is associated with poor prognosis of Community-acquired Pneumonia［J］. Infect Dis (Lond), 2017, 49(4):251-260. ［27］Bello S, Mincholé E, Fandos S, et al. Inflammatory response in mixed viral-bacterial community-acquired pneumonia［J］. BMC Pulm Med, 2014, 14:123. ［28］Que YA, Virgini V, Lozeron ED, et al. Low C-reactive protein values at admission predict mortality in patients with severe community-acquired pneumonia caused by Streptococcus pneumoniae that require intensive care management［J］. Infection, 2015, 43(2):193-199. ［29］Zhuang Q, Zeng Y, Shi Y. ［Coagulopathy correlates with outcomes in patients with community- acquired pneumonia］［J］. Zhonghua Jie He He Hu Xi Za Zhi, 2014, 37(6):406-410. ［30］Nastasijevic Borovac D, Radjenovic Petkovic T, Pejcic T, et al. Role of D-dimer in predicting mortality in patients with community-acquired pneumonia［J］. Med Glas (Zenica), 2014, 11(1):37-43. ［31］Salluh JIF, Rabello LSCF, Rosolem MM, et al. The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission［J］. Journal of critical care, 2011, 26(5):496-501. ［32］Duarte JC, Tavares e Castro A, Silva R, et al. Prognostic value of plasma D-dimer level in adults with community-acquired pneumonia: a prospective study［J］. Rev Port Pneumol (2006), 2015, 21(4):218-219. ［33］Snijders D, Schoorl M, Schoorl M, et al. D-dimer levels in assessing severity and clinical outcome in patients with community-〖JP〗acquired pneumonia. A secondary analysis of a randomised clinical trial［J］. Eur J Intern Med, 2012, 23(5):436-441. ［34］Agapakis DI, Tsantilas D, Psarris P, et al. Coagulation and inflammation biomarkers may help predict the severity of community-〖JP〗acquired pneumonia［J］. Respirology, 2010, 15(5):796-803. ［35］Bermejo-Martin JF, Cilloniz C, Mendez R, et al. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality［J］. EBioMedicine, 2017, 24:231-236. ［36］Bello S, Fandos S, Lasierra AB, et al. Red blood cell distribution width ［RDW］ and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin［J］. Respir Med, 2015, 109(9):1193-1206. ［37］Curbelo J, Luquero Bueno S, Galván-Román JM, et al. Inflammation biomarkers in blood as mortality predictors in community-acquired pneumonia admitted patients: Importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio［J］. PloS one, 2017, 12(3):e0173947. ［38］Cataudella E, Giraffa CM, Di Marca S, et al. Neutrophil-To-Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Community-Acquired Pneumonia［J］. J Am Geriatr Soc, 2017, 65(8):1796-1801. ［39］Usuda D, Sangen R, Hashimoto Y, et al. Validation of a B-type natriuretic peptide as a prognostic marker in pneumonia patients: a prospective cohort study［J］. BMJ open, 2016, 6(2):e010440. ［40］Li J, Ye H, Zhao L. B-type natriuretic peptide in predicting the severity of community-acquired pneumonia［J］. World J Emerg Med, 2015, 6(2):131-136. ［41］Christ-Crain M, Breidthardt T, Stolz D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia［J］. J Intern Med, 2008, 264(2):166-176. ［42］Saballs M, Parra S, Sahun P, et al. HDL-c levels predict the presence of pleural effusion and the clinical outcome of community-acquired pneumonia［J］. Springerplus, 2016, 5(1):1491. ［43］Gwak MH, Jo S, Jeong T, et al. Initial serum lactate level is associated with inpatient mortality in patients with community-acquired pneumonia［J］. Am J Emerg Med, 2015, 33(5):685-690. ［44］Bolatkale M, Duger M, lfer G, et al. A novel biochemical marker for community-acquired pneumonia: Ischemia-modified albumin［J］. Am JEmerg Med, 2017, 35(8):1121-1125. ［45］Andrijevic I, Matijasevic J, Andrijevic L, et al. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia［J］. Ann Thorac Med, 2014, 9(3):162-167. ［46］Yong KK, Chang JH, Chien MH, et al. Plasma Monocyte Chemoattractant Protein-1 Level as a Predictor of the Severity of Community-Acquired Pneumonia［J］. Int JMol Sci, 2016, 17(2). pii:E179. ［47］Chang PY, Tsao SM, Chang JH, et al. Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia［J］. Clin Chim Acta; 2016, 463:174-180. ［48］Klouche K, Cristol JP, Devin J, et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients［J］. Ann Intensive Care, 2016, 6(1):59. ［49］Kim JW, Hong DY, Lee KR, et al. Usefulness of plasma neutrophil gelatinase-associated lipocalin concentration for predicting the severity and mortality of patients with community-acquired pneumonia［J］. Clin Chim Acta,2016, 462:140-145. ［50］Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia［J］. Am J Respir Crit Care Med, 2007, 176(9):913-920. ［51］Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia ［ISRCTN04176397］［J］. Crit Care, 2006, 10(3):R96. ［52］Krüger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ［J］. Intensive Care Med, 2007, 33(12):2069-2078. ［53］Julián-Jiménez A, Timón Zapata J, Laserna Mendieta EJ, et al. Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department［J］. Enferm Infecc Microbiol Clin, 2014, 32(4):225-235. ［54］Nickler M, Schaffner D, Christ-Crain M, et al. Prospective evaluation of biomarkers for prediction of quality of life in community-acquired pneumonia［J］. Clin Chem Lab Med, 2016, 54(11):1831-1846. ［55］Suberviola B, Castellanos-Ortega A, Llorca J, et al. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia［J］. Swiss Med Wkly, 2012, 142:w13542. ［56］Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia［J］. Crit Care, 2010, 14(1):203.